Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1992 8
1993 11
1994 17
1995 19
1996 18
1997 16
1998 19
1999 21
2000 17
2001 20
2002 19
2003 18
2004 18
2005 21
2006 27
2007 18
2008 22
2009 25
2010 35
2011 30
2012 30
2013 35
2014 43
2015 38
2016 27
2017 22
2018 34
2019 34
2020 35
2021 34
2022 40
2023 31
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

753 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean rare in apl (702 results)?
Acute promyelocytic leukemia current treatment algorithms.
Yilmaz M, Kantarjian H, Ravandi F. Yilmaz M, et al. Blood Cancer J. 2021 Jun 30;11(6):123. doi: 10.1038/s41408-021-00514-3. Blood Cancer J. 2021. PMID: 34193815 Free PMC article. Review.
APL, accounting for 10-15% of the newly diagnosed AML cases, results from a balanced translocation, t(15;17) (q22;q12-21), which leads to the fusion of the promyelocytic leukemia (PML) gene with the retinoic acid receptor alpha (RARA) gene. The PML-RARA fusio
APL, accounting for 10-15% of the newly diagnosed AML cases, results from a balanced translocation, t(15;17) (q22;q12-21), which lead
RARA fusion genes in acute promyelocytic leukemia: a review.
De Braekeleer E, Douet-Guilbert N, De Braekeleer M. De Braekeleer E, et al. Expert Rev Hematol. 2014 Jun;7(3):347-57. doi: 10.1586/17474086.2014.903794. Epub 2014 Apr 10. Expert Rev Hematol. 2014. PMID: 24720386 Review.
The t(15;17)(q24;q21), generating a PML-RARA fusion gene, is the hallmark of acute promyelocytic leukemia (APL). ...They participate in protein-protein interactions, associating with RXRA to form hetero-oligomeric complexes that can bind to RARE. They have a dominan …
The t(15;17)(q24;q21), generating a PML-RARA fusion gene, is the hallmark of acute promyelocytic leukemia (APL). ...They parti …
Acute promyelocytic leukemia (APL): a review of the literature.
Jimenez JJ, Chale RS, Abad AC, Schally AV. Jimenez JJ, et al. Oncotarget. 2020 Mar 17;11(11):992-1003. doi: 10.18632/oncotarget.27513. eCollection 2020 Mar 17. Oncotarget. 2020. PMID: 32215187 Free PMC article. Review.
However, relapsed APL, particularly in the high-risk subset of patients, remains an important clinical problem. ...The probability of relapse is significantly higher in the high-risk subset of patients undergoing treatment for APL; overall approximately 10-20% of …
However, relapsed APL, particularly in the high-risk subset of patients, remains an important clinical problem. ...The probability of …
Genotypic and Phenotypic Characteristics of Acute Promyelocytic Leukemia Translocation Variants.
Mannan A, Muhsen IN, Barragán E, Sanz MA, Mohty M, Hashmi SK, Aljurf M. Mannan A, et al. Hematol Oncol Stem Cell Ther. 2020 Dec;13(4):189-201. doi: 10.1016/j.hemonc.2020.05.007. Epub 2020 May 20. Hematol Oncol Stem Cell Ther. 2020. PMID: 32473106 Free article. Review.
The clinical use of all-trans retinoic acid (ATRA) has transformed APL into the most curable form of AML. The majority of APL cases are characterized by the fusion gene PML-RARA. Although the PML-RARA fusion gene can be detected in almost all APL
The clinical use of all-trans retinoic acid (ATRA) has transformed APL into the most curable form of AML. The majority of APL
Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene.
Liquori A, Ibañez M, Sargas C, Sanz MÁ, Barragán E, Cervera J. Liquori A, et al. Cancers (Basel). 2020 Mar 8;12(3):624. doi: 10.3390/cancers12030624. Cancers (Basel). 2020. PMID: 32182684 Free PMC article. Review.
APL is defined by the PML-RARA rearrangement as a consequence of the translocation t(15;17)(q24;q21). ...How this mutational spectrum, including point mutations in the PML-RARA fusion gene, could contribute to the 10%-15% of relapsed or resistant APL p
APL is defined by the PML-RARA rearrangement as a consequence of the translocation t(15;17)(q24;q21). ...How this mutational s
A novel RARA-SNX15 fusion in PML-RARA-positive acute promyelocytic leukemia with t(11;17;15)(q13;q21.2;q24.1).
Hirade K, Kusumoto S, Abe A, Noritake H, Ito A, Ri M, Komatsu H, Iida S, Yamamoto Y. Hirade K, et al. Int J Hematol. 2022 Dec;116(6):956-960. doi: 10.1007/s12185-022-03421-w. Epub 2022 Jul 19. Int J Hematol. 2022. PMID: 35854096
In addition, the reciprocal fusion RARA-PML is present in over 80% of t(15;17) APL cases. The bcr3 types of RARA-PML and RARA-PLZF in particular are reciprocal fusions that contribute to leukemogenesis. ...Co-immunoprecipitation analysis revealed that …
In addition, the reciprocal fusion RARA-PML is present in over 80% of t(15;17) APL cases. The bcr3 types of RARA-PML an …
Identification of concurrent STAT3::RARA and RARA::STAT5b fusions in a variant APL case.
Tao T, Cen J, Xu C, Chen Y, Cao Y, Gong Y, Zhu M, Chen S, Zhang Q, Yao L. Tao T, et al. Mol Carcinog. 2024 Apr;63(4):558-562. doi: 10.1002/mc.23672. Epub 2023 Dec 28. Mol Carcinog. 2024. PMID: 38153216
In a subset of patients with APL, t (15;17) (q22;q21) and PML::RARA fusion cannot be detected. In this report, we identified the coexistence of STAT3::RARA and RARA::STAT5b fusions for the first time in a variant APL patient lacking t (15;17)(q2 …
In a subset of patients with APL, t (15;17) (q22;q21) and PML::RARA fusion cannot be detected. In this report, we identified t …
Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function.
Bercier P, Wang QQ, Zang N, Zhang J, Yang C, Maimaitiyiming Y, Abou-Ghali M, Berthier C, Wu C, Niwa-Kawakita M, Dirami T, Geoffroy MC, Ferhi O, Quentin S, Benhenda S, Ogra Y, Gueroui Z, Zhou C, Naranmandura H, de Thé H, Lallemand-Breitenbach V. Bercier P, et al. Cancer Discov. 2023 Dec 12;13(12):2548-2565. doi: 10.1158/2159-8290.CD-23-0453. Cancer Discov. 2023. PMID: 37655965 Free PMC article.
PML nuclear bodies (NB) are disrupted in PML-RARA-driven acute promyelocytic leukemia (APL). Arsenic trioxide (ATO) cures 70% of patients with APL, driving PML-RARA degradation and NB reformation. In non-APL cells, arsenic binding onto PML also …
PML nuclear bodies (NB) are disrupted in PML-RARA-driven acute promyelocytic leukemia (APL). Arsenic trioxide (ATO) cures 70% …
Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis.
Guarnera L, Ottone T, Fabiani E, Divona M, Savi A, Travaglini S, Falconi G, Panetta P, Rapanotti MC, Voso MT. Guarnera L, et al. Front Oncol. 2022 Apr 12;12:871590. doi: 10.3389/fonc.2022.871590. eCollection 2022. Front Oncol. 2022. PMID: 35494081 Free PMC article. Review.
Acute promyelocytic leukemia (APL) accounts for 10-15% of newly diagnosed acute myeloid leukemias (AML) and is typically caused by the fusion of promyelocytic leukemia with retinoic acid receptor alpha (RARA) gene. ...A small percentage of APLs (around 2%) is caused …
Acute promyelocytic leukemia (APL) accounts for 10-15% of newly diagnosed acute myeloid leukemias (AML) and is typically caused by th …
Curing APL through PML/RARA degradation by As2O3.
Lallemand-Breitenbach V, Zhu J, Chen Z, de Thé H. Lallemand-Breitenbach V, et al. Trends Mol Med. 2012 Jan;18(1):36-42. doi: 10.1016/j.molmed.2011.10.001. Epub 2011 Nov 4. Trends Mol Med. 2012. PMID: 22056243 Review.
Acute promyelocytic leukemia (APL) is a hematological malignancy driven by the PML/RARA oncogene. ...These were both shown a posteriori to target PML/RARA, explaining their exquisite specificity for APL. Arsenic, as a single agent, cures up to 70% of p …
Acute promyelocytic leukemia (APL) is a hematological malignancy driven by the PML/RARA oncogene. ...These were both shown a p …
753 results